Neovascular age-related macular degeneration of all subtypes

Clinical trials for Neovascular age-related macular degeneration of all subtypes explained in plain language.

Never miss a new study

Get alerted when new Neovascular age-related macular degeneration of all subtypes trials appear

Sign up with your email to follow new studies for Neovascular age-related macular degeneration of all subtypes, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Can fewer eye injections dry the retina in wet AMD?

Disease control Completed

Researchers are studying aflibercept (Eylea), an anti-VEGF drug given as an injection into the eye, in adults aged 50 and older with wet age-related macular degeneration. Everyone in the trial receives three monthly loading doses over 12 weeks. The team uses detailed retinal scan…

Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OF ALL SUBTYPES

Phase 4 • Sponsor: University Hospital, Bordeaux • Aim: Disease control

Last updated Sep 19, 2026 00:00 UTC

Neovascular age-related macular degeneration of all subtypes

Get alerted when new Neovascular age-related macular degeneration of all subtypes trials appear

Can fewer eye injections dry the retina in wet AMD?